Towards novel paradigms for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Cancer arises from accumulated genetic/epigenetic abnormalities, transforming normal cells into malignant ones.
• Despite advances in understanding cancer biology and epigenetics, curative targeted therapies remain limited, with toxicity being a major concern.
• Cancer remains a leading global cause of death, necessitating improved therapeutic strategies.

Purpose of the Study:

• To review the current state of cancer therapy, emphasizing target selectivity.
• To discuss strategies for enhancing tumor-selective death and overcoming treatment resistance.
• To explore novel therapeutic avenues, including targeting tumor-initiating cells.

Main Methods:

• Recapitulation and discussion of current concepts and therapies.
• Analysis of strategies targeting tumor-specific features (oncofusion proteins, kinase activity, epigenetics).
• Evaluation of methods for inducing tumor-selective death (oncolytic viruses, tumoricidal proteins, signaling pathways, TRAIL pathway).

Main Results:

• Current therapies often lack sufficient target selectivity, leading to toxicity and limited cures.
• Targeting tumor-specific features and inducing selective cell death show promise.
• The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway is a key system for eradicating malignant cells.
• Targeting tumor-initiating cells (TICs) is crucial for preventing relapse and achieving remission.

Conclusions:

• Improving target selectivity is paramount for effective cancer therapy.
• Novel strategies targeting tumor-specific vulnerabilities and tumor-initiating cells are essential for advancing cancer treatment.
• Further research into pathways like TRAIL and targeting TICs may offer new avenues for cancer cure.